Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06531499 · ClinicalTrials.gov registry record · Phase 1

A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study

A Phase 1 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Novartis Pharmaceuticals.

Recruiting
Registry status
Phase 1
Development phase
106
Enrollment target
20
Study locations

NCT06531499 is a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 106 participants, below the 196-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (46% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06531499, a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.

RECRUITING
Registry status
Phase 1
Development phase
106 participants
Enrollment target
20
Study locations

Study Summary

The purpose of the study is to assess and evaluate dosimetry, safety, and tolerability following administration of up to 12 cycles of (177Lu) vipivotide tetraxetan (also referred to as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereafter identified as AAA617) in taxane-naïve adult participants with PSMA-positive mCRPC who progressed on a prior ARPI treatment with normal renal function or mild renal impairment (eGFR ≥ 60ml/min).

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer

Interventions

  • DRUG AAA617
  • DRUG Gonadotropin-releasing hormone (GnRH) analogues
  • DRUG Gonadotropin-releasing hormone (GnRH) antagonists

Study Locations (20)

Other

  • Novartis Investigative Site - Aachen
  • Novartis Investigative Site - Berlin
  • Novartis Investigative Site - Essen
  • Novartis Investigative Site - München
  • Novartis Investigative Site - Rostock
  • Novartis Investigative Site - Barcelona
  • Novartis Investigative Site - Bellinzona
  • Novartis Investigative Site - Bern

California

  • University of California LA - Los Angeles
  • Stanford University - Palo Alto

North Rhine-Westphalia

  • Novartis Investigative Site - Cologne
  • Novartis Investigative Site - Wuppertal

Minnesota

  • Mayo Clinic Rochester - Rochester

Missouri

  • Wash U School of Medicine - St Louis

Nebraska

  • Nebraska Cancer Specialists - Omaha

Gelderland

  • Novartis Investigative Site - Nijmegen

A Coruna

  • Novartis Investigative Site - Santiago Compostela

Trial Details

FieldValue
Enrollment Target 106 participants
Start Date 2024-11-11
Est. Completion 2028-11-24
Phase Phase 1

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06531499

The ClinicalTrials.gov registry entry for NCT06531499 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 196-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (46% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which AAA617 is the first listed.

NCT06531499 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, California, North Rhine-Westphalia.

Frequently Asked Questions

What is clinical trial NCT06531499 about?

NCT06531499 is a clinical study titled "A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study". The purpose of the study is to assess and evaluate dosimetry, safety, and tolerability following administration of up to 12 cycles of (177Lu) vipivotide tetraxetan (also referred to as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereafter identified as AAA617) in taxane-naïve adult participants with ...

What is the current status of trial NCT06531499?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 106 participants. The study started on 2024-11-11. Estimated completion is 2028-11-24.

What conditions does trial NCT06531499 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.

What interventions are being tested in trial NCT06531499?

The interventions under investigation include: AAA617 (DRUG), Gonadotropin-releasing hormone (GnRH) analogues (DRUG), Gonadotropin-releasing hormone (GnRH) antagonists (DRUG).

Who is sponsoring clinical trial NCT06531499?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06531499 being conducted?

This trial has 20 study locations across California, Minnesota, Missouri, Nebraska, North Rhine-Westphalia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Castration-Resistant Prostate Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.